Companies / Revance Therapeutics, Inc.
Revance Therapeutics, Inc.
RVNCCIK 1479290
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 4, 2025 | Foley Mark J CEO | Other Shares tendered | Common Stock | $3.64M | -997K -97.27% | 27,933 | low |
| May 15, 2023 | Foley Mark J CEO | Sell Open-market sale | Common Stock | $2.43M | -70K -7.09% | 923,212 | medium |
| Mar 9, 2023 | Foley Mark J CEO | Sell Open-market sale | Common Stock | $2.22M | -70K -7.88% | 823,351 | medium |
| Jul 26, 2021 | Rankin Aubrey Executive | Sell Open-market sale | Common Stock | $1.65M | -55K -13.46% | 355,943 | medium |
| Oct 13, 2022 | Foley Mark J CEO | Other Withheld for taxes | Common Stock | $1.33M | -49K -6.43% | 717,487 | low |
| Jul 28, 2021 | Rankin Aubrey Executive | Sell Open-market sale | Common Stock | $1.03M | -34K -9.65% | 321,611 | medium |
| Oct 13, 2021 | Foley Mark J CEO | Other Withheld for taxes | Common Stock | $971.6K | -42K -5.19% | 769,065 | low |
| Jun 9, 2023 | Foley Mark J CEO | Sell Open-market sale | Common Stock | $960.9K | -31K -3.39% | 891,933 | medium |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| RVNC | common | 761330109 |